The purpose of the present study was to develop DNA aptamers through a spontaneous cell-based SELEX method (systemic evolution of ligands by exponential enrichment) that specifically binding to cell surface proteins or biomarkers produced by primary cultured tumor endothelial cells (TECs). In solid tumors, new blood vessels are formed through an angiogenesis process, and this plays a critical role in cancer development as well as the development of metastasis. To combat angiogenesis, an appropriate diagnosis and understanding at the molecular level of different cancer types is now a high priority. Our initial study explored the use of the cell-based SELEX method, which has been applied in TECs to generate high affinity DNA aptamers. Our selected DNA aptamer AraHH001 bound specifically and with a high affinity to TECs in the nanomolar range but did not bind to normal skin endothelial cells (skin-ECs) and tumor parenchymal OSRC-II cells. The selected DNA aptamers also bounded to primary cultured human tumor endothelial cells (hTECs) isolated from a clinical patient with a renal carcinoma. Therefore, the development of specific DNA aptamers that bind to TECs is reported here for the first time. We conclude that such new DNA aptamers promise to hold great promise as targeted molecular probes that appear to play a major role in angiogenesis, drug delivery, identification of biomarker as well as in cancer therapy.

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 3886. doi:1538-7445.AM2012-3886